Information on New Approvals and Medication Safety
Colcrys Approval Triggers Questions
Some rheumatologists question the depth of research and the approval’s implications for patient access
Drug Updates
Information on New Approvals and Medication Safety
The Law of Unintended Consequences Rears Its Head
A program to improve drug safety has increased drug prices for patients with gout and FMF
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates: Information on New Approvals and Medication Safety
Information on New Approvals and Medication Safety
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Drug Updates
Information on News Approvals and Medication Safety
H1N1 Influenza A Virus Brings Many Questions, Few Answers
Rheumatologists grapple with vaccine concerns and the impact of medications on response
Drug Updates
Information on New Approvals and Medication Safety